Emerald Health Therapeutics Launches Flavoured Cannabis Oils, Expanding SYNC(TM) Product Line

Combination of appealing natural flavourings and terpenes offers unique consumer experience Emerald also launches new SYNC CBD nanoemulsion-based Fast Action Spray in BC and Saskatchewan Vancouver, British Columbia–(Newsfile Corp. – October 19, 2020) – Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (“Emerald”) has expanded its SYNCTM product line with the launch of new uniquely flavoured CBDContinue reading “Emerald Health Therapeutics Launches Flavoured Cannabis Oils, Expanding SYNC(TM) Product Line”

Emerald Health Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

 – September 1, 2020) – Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (“Emerald”) reported financial results for the three and six months ended June 30, 2020. Full versions of the Company’s unaudited condensed interim consolidated financial statements and MD&A can be found on SEDAR at www.sedar.com. “The second quarter was a very solid quarter in allContinue reading “Emerald Health Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update”

Emerald Health Therapeutics Launches New Fast-Acting Cannabis Spray Products Offering Consumers Significantly Improved Predictability and Control of Effects

SYNC(TM) Nano Fast Action Spray uses nanoemulsion technology to enable rapid onset and shorter duration of effects; the first THC product is in-market, with CBD to follow  –  Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (“Emerald”)  has launched the first product in its adult-use SYNCTM Nano fast-acting cannabis spray product line. SYNCTM 15 Nano THC FastContinue reading “Emerald Health Therapeutics Launches New Fast-Acting Cannabis Spray Products Offering Consumers Significantly Improved Predictability and Control of Effects”

Emerald Health Therapeutics Announces New At-the-Market Equity Program

 – August 13, 2020) – Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (the “Company”) today announced that it has established an at-the-market equity program (“ATM Program”) that allows the Company to issue common shares from treasury (“Common Shares”) having an aggregate gross sales price of up to $3.25 million to the public from time toContinue reading “Emerald Health Therapeutics Announces New At-the-Market Equity Program”

Emerald Health Therapeutics and Quinto Resources Enter into Share Purchase Agreement for Sale of Quebec Cannabis Business

– July 31, 2020) – Emerald Health Therapeutics, Inc. (TSXV: EMH)  (“Emerald”) and Quinto Resources Inc. (“Quinto”) (TSXV: QIT) today announced that they have entered into a share purchase agreement dated July 30, 2020 (the “Agreement”) in respect of the sale of Emerald’s wholly-owned subsidiaries, Verdélite Sciences, Inc. (“Verdélite Sciences”) and Verdélite Property Holdings, Inc.Continue reading “Emerald Health Therapeutics and Quinto Resources Enter into Share Purchase Agreement for Sale of Quebec Cannabis Business”

Emerald Health Therapeutics’ Pure Sunfarms Joint Venture Begins Shipping Branded Products to Manitoba

Pure Sunfarms remains top-selling dried cannabis brand with Ontario Cannabis Store1 and achieves sales records in July — Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that its joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has begun shipping branded, packaged dried flower products to Manitoba’s licensed private sector retailers, withContinue reading “Emerald Health Therapeutics’ Pure Sunfarms Joint Venture Begins Shipping Branded Products to Manitoba”

Emerald Health Therapeutics Announces Completion of Accordion Provision of Pure Sunfarms’ Credit Facility

Expanded facility provides additional financial resources and flexibility as Pure Sunfarms continues to build on its success to date as a leading Canadian cannabis producer and brand — Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that its joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has further expanded itsContinue reading “Emerald Health Therapeutics Announces Completion of Accordion Provision of Pure Sunfarms’ Credit Facility”

Emerald Health Therapeutics’ Verdélite Launches Souvenir™ Cannabis Brand in Québec

Verdélite offers craft cannabis products in its home province for Québec consumers  — Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announces that its Verdélite Sciences subsidiary in St. Eustache, Québec, has launched its new Souvenir cannabis brand in the province. The Souvenir product line initially consists of select dried flower products from two Emerald cultivars, Grapefruit GG4Continue reading “Emerald Health Therapeutics’ Verdélite Launches Souvenir™ Cannabis Brand in Québec”

Emerald Health Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

— Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) reported financial results for the quarter and ended March 31, 2020. Full versions of the Company’s unaudited condensed interim consolidated financial statements and MD&A can be found on SEDAR at www.sedar.com. “In the first quarter and year to date, the benefits of Emerald’s significant restructuring andContinue reading “Emerald Health Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update”